[1]文 静.HBV感染患者血清25（OH）D3含量与HBV DNA载量的相关性[J].医学信息,2022,35(21):81-83，91.[doi:10.3969/j.issn.1006-1959.2022.21.018]
　WEN Jing.Correlation Between Serum 25(OH)D3 Content and HBV DNA Load in Patients with HBV Infection[J].Journal of Medical Information,2022,35(21):81-83，91.[doi:10.3969/j.issn.1006-1959.2022.21.018]
点击复制

HBV感染患者血清25（OH）D3含量与HBV DNA载量的相关性()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年21期
页码:
81-83，91
栏目:
论著
出版日期:
2022-11-01

文章信息/Info

Title:
Correlation Between Serum 25(OH)D3 Content and HBV DNA Load in Patients with HBV Infection
文章编号:
1006-1959（2022）21-0081-04
作者:
文 静
（空军军医大学西京医院检验科，陕西 西安 710032）
Author(s):
WEN Jing
(Department of Clinical Laboratory,Xijing Hospital of Air Force Medical University,Xi’an 710032,Shaanxi,China)
关键词:
乙型肝炎病毒; 血清25（OH）D3; HBV DNA载量
Keywords:
Hepatitis B virus; Serum 25(OH)D3;  HBV DNA load
分类号:
R446.5
DOI:
10.3969/j.issn.1006-1959.2022.21.018
文献标志码:
A
摘要:
目的 研究乙型肝炎病毒（HBV）感染患者血清25-羟维生素D3[25（OH）D3]含量与HBV DNA载量的相关性。方法 选取2020年6月-2021年6月我院诊治的92例HBV感染患者为观察组，并选取同期在我院体检健康者90例为对照组，均进行血清25（OH）D3含量与HBV DNA载量检测，比较两组血清25（OH）D3含量、不同临床期患者血清25（OH）D3含量和HBV DNA载量、不同血清25（OH）D3含量患者HBV DNA载量表达阴性率和不同水平HBV DNA载量阳性率比例，并采用血清25（OH）D3含量与HBV DNA载量的相关性。结果 观察组血清25（OH）D3水平低于对照组（P＜0.05）。慢性乙肝肝炎患者血清25（OH）D3含量均高于无症状携带、原发性肝细胞性肝癌、肝炎肝硬化患者（P＜0.05）；原发性肝细胞性肝癌患者HBV DNA载量高于无症状携带、慢性乙肝肝炎、肝炎肝硬化患者（P＜0.05）。血清25（OH）D3含量≥30 ng/ml患者HBV DNA载量阴性率高于血清25（OH）D3含量20~29.90 ng/ml、≤19.9 ng/ml患者，且HBV DNA载量＜103 IU/ml阳性率占比高于20~29.90 ng/ml和≤19.9 ng/ml组（P＜0.05）；HBV DNA载量103~105 IU/ml阳性率占比小于20~29.90 ng/ml和≤19.9 ng/ml患者，但20~29.90 ng/ml和≤19.9 ng/ml患者比较，差异无统计学意义（P＞0.05）；HBV DNA载量＞105 IU/ml阳性率占比低于20~29.90 ng/ml和≤19.9 ng/ml患者，且20~29.90 ng/ml患者低于≤19.9 ng/ml患者（P＜0.05）。Spearman相关性分析显示，HBV感染患者血清25（OH）D3含量与HBV DNA载量呈负相关（r=-0.429，P=0.015）。结论 HBV感染患者血清25（OH）D3含量较低，而不同临床分期患者血清25（OH）D3含量和HBV DNA载量存在差异，其中HBV DNA载量随病情发展逐渐升高，且血清25（OH）D3含量与HBV DNA载量呈负相关。
Abstract:
Objective To study the correlation between serum 25-hydroxyvitamin D3 [25(OH)D3] content and HBV DNA load in patients with hepatitis B virus (HBV) infection.Methods A total of 92 patients with HBV infection diagnosed and treated in our hospital from June 2020 to June 2021 were selected as the observation group, and 90 healthy people who underwent physical examination in our hospital during the same period were selected as the control group. Serum 25(OH)D3 content and HBV DNA load were detected. The serum 25(OH)D3 content, serum 25(OH)D3 content and HBV DNA load in patients with different clinical stages, the negative rate of HBV DNA load expression in patients with different serum 25(OH)D3 content and the positive rate of HBV DNA load at different levels were compared between the two groups. The correlation between serum 25(OH)D3 content and HBV DNA load was analyzed.Results The serum 25(OH)D3 level in the observation group was lower than that in the control group (P<0.05). The level of serum 25(OH)D3 in patients with chronic hepatitis B was higher than that in asymptomatic carriers, primary hepatocellular carcinoma and liver cirrhosis (P<0.05). The HBV DNA load in patients with primary hepatocellular carcinoma was higher than that in patients with asymptomatic carrier, chronic hepatitis B and hepatitis cirrhosis (P<0.05). The negative rate of HBV DNA load in patients with serum 25(OH)D3 content≥30 ng/ml was higher than that in patients with serum 25(OH)D3 content 20-29.90 ng/ml and ≤19.9 ng/ml, and the positive rate of HBV DNA load <103 IU/ml was higher than that in 20-29.90 ng/ml and ≤19.9 ng/ml groups (P<0.05); the positive rate of HBV DNA load 103-105 IU/ml was less than 20-29.90 ng/ml and ≤19.9 ng/ml, but there was no significant difference between 20-29.90 ng/ml and ≤ 19.9 ng/ml (P>0.05). The positive rate of HBV DNA load>105 IU/ml was lower than that of patients with 20-29.90 ng/ml and ≤19.9 ng/ml, and that of patients with 20-29.90 ng/ml was lower than that of patients with ≤19.9 ng/ml (P<0.05). Spearman correlation analysis showed that serum 25(OH)D3 content was negatively correlated with HBV DNA load in patients with HBV infection (r=-0.429, P=0.015).Conclusion The serum 25(OH)D3 content in patients with HBV infection is low, and there are differences in serum 25(OH)D3 content and HBV DNA load in patients with different clinical stages. The HBV DNA load gradually increases with the development of the disease, and the serum 25(OH)D3 content is negatively correlated with HBV DNA load.

参考文献/References:

[1]姚明解,陈华楠,钱相君,等.乙型肝炎病毒感染相关肝癌患者术前异常凝血酶原和甲胎蛋白水平对其预后影响的研究[J].中国实用内科杂志,2019,39(7):640-643.[2]袁媛,陈骥,王亚莉.HBeAg阴性慢性乙肝合并肝硬化患者血清HBV-DNA水平与肝功能的关系[J].山东医药,2017,57(1):81-83.[3]De Crignis E,Hossain T,Romal S,et al.Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma[J].Elife,2021,10:e60747.[4]沈敏,林明强,冯奇桃,等.HBV相关慢加亚急性肝衰竭患者中Th17细胞、Treg细胞的变化及其与肝功能和HBV-DNA载量间的研究[J].海南医学,2016,27(5):692-696.[5]Li MH,Zhang L,Zhang D,et al.Plasmacytoid Dendritic Cell Function and Cytokine Network Profiles in Patients with Acute or Chronic Hepatitis B Virus Infection[J].Chin Med J (Engl),2018,131(1):43-49.[6]鲍腾,胡庆刚,叶珺,等.HBsAg水平在慢性HBV感染者疾病进展中的动态监测价值[J].临床肝胆病杂志,2017,33(8):1475-1478.[7]马建和,徐飞,王雅杰.HBV前S基因突变与HBV感染者慢加急性肝衰竭的相关研究[J].标记免疫分析与临床,2018,25(10):1460-1463.[8]应盛,董飞波,孙毅,等.COBAS TaqMan系统检测血清 HBV-DNA 的临床价值探讨[J].中华医院感染学杂志,2017,27(2):305-308.[9]中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版)[J].临床肝胆病杂志,2019,35(12):1620-1623.[10]Li Q,Lu C,Li W,et al.Globulin-platelet model predicts significant fibrosis and cirrhosis in CHB patients with high HBV DNA and mildly elevated alanine transaminase levels[J].Clin Exp Med,2018,18(1):71-78.[11]刘蕾,赵鹏,邢雪梅,等.乙型肝炎后肝硬化患者血清AFP-L3、GP-73、CEA与HBV-DNA载量的关系及在肝硬化分级诊断中的价值[J].检验医学与临床,2018,15(3):320-322.[12]陈琼,陈蓉,曾艺馨,等.乙型肝炎病毒感染患者HBV－DNA载量与血清及肝纤维化标志物的关系[J].中华医院感染学杂志,2017,27(15):3487-3489.[13]王玲,蔚梅芳,武希润,等.乙肝肝硬化患者外周血25-（OH）D3,Th17细胞,CD4+Treg 细胞的变化及意义[J].山西医科大学学报,2017,48(12):1233-1235.[13]欧阳福,杨丽莎,庞爱萍,等.25－羟维生素D3与乙型肝 炎肝硬化患者外周血T淋巴细胞亚群的关系[J].广东医学,2018,39(2):261-264.[14]巩灿灿.血清25－羟维生素D3与慢性HBV感染者的相关性研究[D].济南:山东大学,2017.[15]白娜,杜萍萍.血清25(OH)维生素D水平与原发性肝癌的相关性分析[J].山西医药杂志,2020,11(15):42-45.[16]刘诗芳,王国慧.婴幼儿血清25-羟维生素D3影响因素分析及药物联合行为干预的效果[J].中国妇幼保健,2019,34(1):105-109.[17]周连卉.老年非酒精性脂肪性肝病患者血25-羟维生素D水平与肝纤维化的相关性[J].吉林医学,2018,39(11):2146-2149.[18]张利娟,童巧霞.慢性乙型肝炎肝纤维化患者血清25羟维生素D3水平临床研究[J].中华疾病控制杂志,2018,22(10):1016-1019,1045.[19]王霖霞,苏娜,张云娜,等.25羟维生素D3、hs-CRP与糖尿病视网膜病变相关性研究[J].河北医科大学学报,2018,39(10):1149-1152,1184.[20]吴刚,吴锦瑜.HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3的检测及临床意义[J].医学信息,2018,31(19):96-98.

相似文献/References:

[1]钱熠辉,彭 琼.乙型肝炎病毒感染与结直肠腺瘤的相关性研究[J].医学信息,2019,32(04):81.[doi:10.3969/j.issn.1006-1959.2019.04.027]
　QIAN Yi-hui,PENG Qiong.Correlation between Hepatitis B Virus Infection and Colorectal Adenoma[J].Journal of Medical Information,2019,32(21):81.[doi:10.3969/j.issn.1006-1959.2019.04.027]
[2]杨美玲,黄荷凤.HBV暴露对子代影响的研究进展[J].医学信息,2019,32(10):32.[doi:10.3969/j.issn.1006-1959.2019.10.012]
　YANG Mei-ling,HUANG He-feng.Advances in Research on the Effects of HBV Exposure on Offspring[J].Journal of Medical Information,2019,32(21):32.[doi:10.3969/j.issn.1006-1959.2019.10.012]
[3]唐细田,肖 琳,徐彤慧.化学发光法和酶联免疫法在乙型肝炎病毒血清学检验中的效果比较[J].医学信息,2019,32(22):164.[doi:10.3969/j.issn.1006-1959.2019.22.057]
　TANG Xi-tian,XIAO Lin,XU Tong-hui.Comparison of the Effects of Chemiluminescence and Enzyme-linked Immunosorbent Assay on Serological Test of Hepatitis B Virus[J].Journal of Medical Information,2019,32(21):164.[doi:10.3969/j.issn.1006-1959.2019.22.057]
[4]苏振华.乙肝病毒标记物阳性表型血清标本乙型肝炎病毒HBV-DNA临床检验分析[J].医学信息,2020,33(04):179.[doi:10.3969/j.issn.1006-1959.2020.04.061]
　SU Zhen-hua.Clinical Analysis of Hepatitis B Virus HBV-DNA in Serum Specimen with Hepatitis B Virus Markers Positive[J].Journal of Medical Information,2020,33(21):179.[doi:10.3969/j.issn.1006-1959.2020.04.061]
[5]党便利,孙永涛,康文臻.HBcrAg在慢性乙型肝炎中研究进展[J].医学信息,2020,33(17):23.[doi:10.3969/j.issn.1006-1959.2020.17.007]
　DANG Bian-li,SUN Yong-tao,KANG Wen-zhen.Research Progress of HBcrAg in Chronic Hepatitis B[J].Journal of Medical Information,2020,33(21):23.[doi:10.3969/j.issn.1006-1959.2020.17.007]
[6]帅苍南,张玉亭,刘 敏,等.抗慢性乙型肝炎肝纤维化中成药研究进展[J].医学信息,2022,35(08):38.[doi:10.3969/j.issn.1006-1959.2022.08.010]
　SHUAI Cang-nan,ZHANG Yu-ting,LIU Min,et al.Research Progress of Anti-chronic Hepatitis B Liver Fibrosis Chinese Patent Medicine[J].Journal of Medical Information,2022,35(21):38.[doi:10.3969/j.issn.1006-1959.2022.08.010]

更新日期/Last Update: 1900-01-01